

COPY OF PAPERS
INITIALLY FILED

RECEIVED

MAR 22 2002

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/823,240	TECH CENTER 1600/2900 656/7064
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: March 30, 2001	CONFIRMATION NO.: 6318
		APPLICANT: Gertler et al.	
		GROUP ART UNIT: 1645 1636	EXAMINER: Unassigned <i>McKelvey</i>
Sheet MAR 20 2002	of 1		

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
<i>Tme</i>	B3	PCT	US01/10249		International Search Report	03/30/2001	
↓	B4	WO	01/74378	A2	Regents of the University of CA	10/11/2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.				Translation (Y/N)	
<i>Tme</i>	C6	ASZODI, A. et al., "The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function", <i>The EMBO Journal</i> , 1999, Pages 37-48, Vol. 18, No. 1, European Molecular Biology Organization					
	C7	BEAR, J.E. et al., "Negative Regulation of Fibroblast Motility by Ena/VASP Proteins", <i>Cell</i> , June 23, 2000, Pages 717-728, Vol. 101, Cell Press					
	C8	GERTLER, F.B. et al., "Mena, a Relative of VASP and Drosophila Enabled, is Implicated in the Control of Microfilament Dynamics", <i>Cell</i> , October 18, 1996, Pages 227-239, Vol. 87, Cell Press					
	C9	HAUSER, W. et al., "Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice", <i>Proc. Natl. Acad. Sci. USA</i> , July 1999, Pages 8120-8125, Vol. 96					
	C10	KRAUSE, M. et al., "Fyn-binding Protein (Fyb)/SLP-76-associated Protein (SLAP), Ena/Vasodilator-stimulated Phosphoprotein (VASP) Proteins and the Arp2/3 Complex Link T Cell Receptor (TCR) Signaling to the Actin Cytoskeleton", <i>The Journal of Cell Biology</i> , April 3, 2000, Pages 181-194, Vol. 149, No. 1, The Rockefeller University Press					
	C11	LIU, K. et al., "Reversible Tumorigenesis Induced by Deficiency of Vasodilator-Stimulated Phosphoprotein", <i>Molecular and Cellular Biology</i> , May 1999, Pages 3696-3703, Vol. 19, No. 5, American Society for Microbiology					
	C12	MACHESKY, L.M., "Putting on the Brakes: A Negative Regulatory Function for Ena/VASP Proteins in Cell Migration", <i>Cell</i> , June 23, 2000, Pages 685-688, Vol. 101, Cell Press					
✓	C13	REINHARD, M. et al., "Actin-based motility: stop and go with Ena/VASP proteins", <i>TRENDS in Biochemical Sciences</i> , April 2001, Pages 243-249, Vol. 26, No. 4					

EXAMINER <i>Peng a McKelvey</i>	DATE CONSIDERED <i>11/28/03</i>
------------------------------------	------------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

600013.1